Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study

BACKGROUND: Clinical trials of immune checkpoint inhibitors (ICIs) often do not include patients with advanced chronic kidney disease (CKD). We aimed to determine the safety of ICIs in patients with cancer and advanced CKD (stages 4-5 CKD, estimated glomerular filtration rate [eGFR] <30 mL/minute...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiu, Bruce C, Strohbehn, Ian A, Zhao, Sophia, Ouyang, Tianqi, Hanna, Paul, Wang, Qiyu, Gupta, Shruti, Leaf, David E, Reynolds, Kerry L, Sise, Meghan E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Immuno-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243781/
https://www.ncbi.nlm.nih.gov/pubmed/36821637
http://dx.doi.org/10.1093/oncolo/oyad001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243781/
https://www.ncbi.nlm.nih.gov/pubmed/36821637
http://dx.doi.org/10.1093/oncolo/oyad001

Ejemplares similares